STOCK TITAN

Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its third quarter of fiscal 2021 ended August 31, 2021 on Wednesday, October 13, 2021.

A conference call will be held on October 13, 2021 at 8:30 a.m. (ET) to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque and other members of the management team will be available to answer questions from participants following prepared remarks.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at https://edge.media-server.com/mmc/p/hwyarfb3. An audio replay of the conference call will be available on the same day starting at 11:30 a.m. (ET) until October 20, 2021 by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 2420948. An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For investor and media inquiries:
Leah Gibson
Senior Director, Investor Relations
617-356-1009
communications@theratech.com


Theratechnologies Inc.

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

60.69M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.